Back to top

Image: Bigstock

Should You Get Rid of Peregrine Pharmaceuticals (PPHM) Now?

Read MoreHide Full Article

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.

One such stock that you may want to consider dropping is Peregrine Pharmaceuticals, Inc. PPHM, which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in PPHM.

A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen one estimate moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from a loss of 43 cents a share a month ago to its current level of a loss of 57 cents.

Also, for the current quarter, Peregrine Pharmaceuticals has seen one downward estimate revision versus no revision in the opposite direction, dragging the consensus estimate down to a loss of 14 cents a share from loss of 12 cents over the past 30 days.   

The stock also has seen some pretty dismal trading lately, as the share price has dropped 12.7% in the past month.

So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.

If you are still interested in the Medical - Biomedical and Genetics industry, you may instead consider a better-ranked stock - Emergent BioSolutions Inc. (EBS - Free Report) . The stock currently sports a Zacks Rank #1 (Strong Buy) and may be a better selection at this time. You can see the complete list of today’s Zacks #1 Rank stocks here.

Wall Street’s Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Emergent Biosolutions Inc. (EBS) - free report >>

Published in